REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot85610.21518/1561-5936-2021-2-43-50Original ArticleCOVID-19: not by vaccine aloneGandelVictor-The International Akademy for Integrational of Sciencen and Business (IAISB)141220212435017032022Copyright © 2021,2021A novel cornavirus infection declared by WHO a COVID-19 pandemic has set the task of raising funds to address the challenge posed by the novel coronavirus SARS-Cov-2 against civilization. The design of drugs with antiviral activity against the novel coronavirus has resulted in the development of several drug candidates. Remdesivir developed by the American company Gilead Sciences Inc. has become one of the first drug, upon which the decision on using it as a pharmacotherapeutic agent was reached. Initially, the drug was created in 2009 for the treatment of other viral diseases but did not show the expected activity. The further development and assessment of pharmacological activity was carried out with the encouragement of public investment in conjunction with and under guidance of the USA Department of Defence and some university laboratories.The findings of clinical trials conducted in different countries have shown the future-oriented outlook for remdesivir for the treatment of patients with COVID-19, which, however, left WHO underwhelmed, as a result it did not recommend the drug as a pharmacotherapy for novel coronavirus infection. After an expert analysis, the Ministry of Health of the Russian Federation included remdesivir in the list of drugs that can be used in the treatment of COVID-19 along with other drugs. The study of the features and circumstances of the launch of remdesivir to the pharmaceutical market allows us to come ever closer to the answer to the fundamental question of the 21st century: SARS-Cov-2 is a design of nature or the result of purposeful anthropogenic activity.COVID-19SARS-CoV-2pandemiccoronavirusCOVID-19SARS-CoV-2Big PharmaremdesivirpharmacotherapyпандемиякоронавирусБольшая Фармаремдесивирфармакотерапия1.Hansen C.H., Michlmayr D., Gubbels S.M., Mølbak K., Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. Lancet. 2021;397(10280):1204–1212. https://doi.org/10.1016/S0140-6736(21)00575-4.2.https://tass.ru/obschestvo/10929771.3.https://tass.ru/obschestvo/10956921.4.Yount B., Curtis K.M., Fritz E. A., Hensley L.E., Jahrling P.B., Prentice E. et. al. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. PNAS. 2003;100(22):12995–13000. https://doi.org/10.1073/pnas.1735582100.5.Eric Ng. Who owns the coronavirus cure? China’s move to patent Gilead’s experimental drug for the novel virus could lead to legal wrangle. South China Morning Poste. Published: 8:00 am, 6 Feb, 2020. Updated: 6:00pm, 14 Feb, 2020.6.Gilead Sciences Statement on Expanding Global Supply of Investigational Antiviral Remdesivir, Foster City, Calif., May 5, 2020. Available at: https://gilead.com/news-and-press/companystatements/gilead-sciences-statement-on-remdesivir-globalsupply.7.WHO recommends against the use of remdesivir in COVID-19 patients, 20 November 2020. Available at: https://who.int/newsroom/feature-stories/detail/who-recommends-against-the-useof-remdesivir-in-COVID-19-patients.8.https://twitter.com/WHO/status/1278715975106355202?s=20.9.Fätkenheuer G., lundgren J., Compassionate Use of Remdesivir in COVID-19. N Engl J Med. 2020;382(25):e101. https://doi.org/10.1056/nejmc2015312.10.Corona-Patienten bleiben mindestens drei Monate immune. Der Spiegel Wissenschaft. 30.04.2020.11.Wendtner C. Wir haben hier nur noch schwere Fälle. Zeite Online, 25. März 2020.12.Лян Т. (ред.). Руководство по профилактике и лечению новой коронавирусной инфекции COVID-19. Первая академическая клиника Университетской школы медицины провинции Чжэнцян; 2020. 96 с. Режим доступа: https://ria.ru/ips/op/COVID_19_Book.pdf.13.Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C. et. al. Remdesivir for the Treatment of COVID-19 – Final Report. N Engl J Med. 2020;383(19):1813–1826.14.http://www.kremlin.ru/multimedia/audio/page/34.15.Фармасинтез, Пресс-центр, новости от 26 ноября 2020 г. Режим доступа: https://pharmasyntez.com/press-center/news/vladimir-putin-i-denis-manturov-otkryli-novoe-farmproizvodstvov-bratske.